http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:43:20 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Forte+Biosciences+%28FBRX%29+files+%24500M+mixed+shelf/26592519.html <p>Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Debt Securities</p><p>Depositary Shares</p><p>Warrants</p><p>Subscription Rights</p><p>Purchase Contracts</p><p>Units</p> http://www.streetinsider.com/Equity+Offerings/Forte+Biosciences+%28FBRX%29+files+%24500M+mixed+shelf/26592519.html Tue, 02 Jun 2026 16:43:20 -0400 FBRX http://www.streetinsider.com/Corporate+News/Forte+Biosciences+%28FBRX%29+files+%24500M+mixed+shelf/26592519.html <p>Forte Biosciences (NASDAQ: FBRX) has filed $500,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Debt Securities</p><p>Depositary Shares</p><p>Warrants</p><p>Subscription Rights</p><p>Purchase Contracts</p><p>Units</p> http://www.streetinsider.com/Corporate+News/Forte+Biosciences+%28FBRX%29+files+%24500M+mixed+shelf/26592519.html Tue, 02 Jun 2026 16:43:20 -0400 FBRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Doberstein+Stephen+K/26592465.html si-local-file:///var/storage/secattach/20260602/26592465.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Doberstein+Stephen+K/26592465.html Tue, 02 Jun 2026 16:40:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Doberstein+Stephen+K/26592465.html si-local-file:///var/storage/secattach/20260602/26592465.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Doberstein+Stephen+K/26592465.html Tue, 02 Jun 2026 16:40:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kapoor+Shivpreet+Singh/26592447.html si-local-file:///var/storage/secattach/20260602/26592447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kapoor+Shivpreet+Singh/26592447.html Tue, 02 Jun 2026 16:39:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kapoor+Shivpreet+Singh/26592447.html si-local-file:///var/storage/secattach/20260602/26592447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kapoor+Shivpreet+Singh/26592447.html Tue, 02 Jun 2026 16:39:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+VINCENT+RICHARD+G/26592437.html si-local-file:///var/storage/secattach/20260602/26592437.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+VINCENT+RICHARD+G/26592437.html Tue, 02 Jun 2026 16:38:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+VINCENT+RICHARD+G/26592437.html si-local-file:///var/storage/secattach/20260602/26592437.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+VINCENT+RICHARD+G/26592437.html Tue, 02 Jun 2026 16:38:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+GRYSKA+DAVID+W/26592419.html si-local-file:///var/storage/secattach/20260602/26592419.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+GRYSKA+DAVID+W/26592419.html Tue, 02 Jun 2026 16:37:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+GRYSKA+DAVID+W/26592419.html si-local-file:///var/storage/secattach/20260602/26592419.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+GRYSKA+DAVID+W/26592419.html Tue, 02 Jun 2026 16:37:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Brun+Scott+C./26592391.html si-local-file:///var/storage/secattach/20260602/26592391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Brun+Scott+C./26592391.html Tue, 02 Jun 2026 16:36:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Brun+Scott+C./26592391.html si-local-file:///var/storage/secattach/20260602/26592391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Brun+Scott+C./26592391.html Tue, 02 Jun 2026 16:36:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kornfeld+Steven/26592365.html si-local-file:///var/storage/secattach/20260602/26592365.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kornfeld+Steven/26592365.html Tue, 02 Jun 2026 16:35:00 -0400 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kornfeld+Steven/26592365.html si-local-file:///var/storage/secattach/20260602/26592365.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Forte+Biosciences%2C+Inc.+++For%3A+May+29++Filed+by%3A+Kornfeld+Steven/26592365.html Tue, 02 Jun 2026 16:35:00 -0400 FBRX O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54533513&amp;newsitemid=20260511415343&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=029376690f131eeca2c3883e050a72e9" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rules/26468669.html Mon, 11 May 2026 16:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Earnings/Forte+Biosciences+%28FBRX%29+Misses+Q1+EPS+by+124c/26467107.html <p>Forte Biosciences (NASDAQ: FBRX) reported Q1 EPS of ($1.24).</p><p>For earnings history and earnings-related data on Forte Biosciences (FBRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=FBRX">click here</a>.</p> http://www.streetinsider.com/Earnings/Forte+Biosciences+%28FBRX%29+Misses+Q1+EPS+by+124c/26467107.html Mon, 11 May 2026 11:27:45 -0400 FBRX http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Announces+First+Quarter+2026+Results+and+Provides+Update/26466122.html <p class="bwalignc"> <i>FB102 Received Fast Track Designation in Celiac Disease</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54532453&amp;newsitemid=20260511177742&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=62c36781447bdd36745dc2630f0e75ca" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. </p><p> “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly,” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Announces+First+Quarter+2026+Results+and+Provides+Update/26466122.html Mon, 11 May 2026 09:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Announces+First+Quarter+2026+Results+and+Provides+Update/26466122.html <p class="bwalignc"> <i>FB102 Received Fast Track Designation in Celiac Disease</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54532453&amp;newsitemid=20260511177742&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=62c36781447bdd36745dc2630f0e75ca" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. </p><p> “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly,” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Announces+First+Quarter+2026+Results+and+Provides+Update/26466122.html Mon, 11 May 2026 09:01:00 -0400 A.50216777 FBRX O.21049479 O.54516537